Tuberculosis drug company TB Alliance revealed on Tuesday the addition of Jan Lundberg to its board of directors.

Dr Lundberg spent eight years as president of Lilly Research Laboratories and executive vice president of Science and Technology at Eli Lilly and Company.

Previously at AstraZeneca, Dr Lundberg was the global head of discovery research, including for infectious diseases and a TB Research facility in Bangalore.

Currently, Dr Lundberg is the cofounder of Aerocrine AB, a board member at Ardelyx, Betagenon and Image Analysis Group, a professor in the Department of Pharmacology at Karolinska Institute in Stockholm as well as a member of several governmental committees in both the EU and the US.